Rejection after a matched related BMT for thalassemia major (TM) may occur in 5-30% of BMTs.
at hours +24 h +32 h and +40 h). Methylprednisolone at 0.5 mg/ kg/day i.v. from day − 1 to +30 and tapered by − 1/3 every 5 days over 15 days and stopped on day +45 was also used (Lucarelli's protocol 6.1). 8 After their first BMT, both patients lost their graft with o5% donor chimerism and transfusion dependency. Both first and second transplant data are summarized in Table 1 .
The treatment protocol was approved by the Pakistan Institute of Medical Sciences review board and the parents of both patients provided written informed consent in accordance with the Declaration of Helsinki.
Both patients had an unremarkable course after their first BMT; however, their second transplant course was noticeable for Pseudomonas aeruginosa bacteremia on day − 1 in Patient 2, which responded to ceftriaxone and amikacin. The duration of neutropenia and transfusion requirements during the first and second BMTs did not seem to differ substantially (see Table 1 ). Both patients now have >90% donor chimerism and are transfusion independent at more than 2 years from their second BMT.
To our knowledge, this is the first report on the use of PTCy as the sole means of preventing rejection of a second BMT. Although this report is limited to only two patients, PTCy allowed for a second engraftment from the same histocompatible donor with little acute toxicity, no additional immunosuppression, no chronic GVHD, long-term full chimerism and transfusion independence. Both these patients were quite young at their first transplant, that is, a subgroup known to be at higher risk for rejection. Abbreviations: Bu = oral Bu; Pdn = prednisone; PTCy = CY 50 mg/kg on day +3 and +4; RBCTx = RBC transfusions; Tt = thiotepa. We have not adjusted the BU dosing based on plasma levels and cannot exclude the possibility that pharmacokinetic differences between the first and second BMTs might have had a role. 10 A liver biopsy was not performed on either child and thus a Pesaro risk group could not be assigned. However, given their age, the absence of hepatomegaly and the limited number of previous red cell transfusions, they most likely belonged to a low-risk group. 1 This preliminary experience suggests that post BMT, CY alone may be safe, tolerable and effective in promoting engraftment and preventing GVHD after the initial rejection of the same matched related donor in TM patients. This proof of principle might be particularly helpful as many transplant centers explore increasingly tolerable first-line preparation regimens that might be associated with decreased mortality and morbidity at a price of increased graft failure. 
